"The Beginning of an Exciting Era": Quantum computing firm IonQ Announces a Major Breakthrough and a Deal with Nvidia

Shares of IonQ surged more than 5% during trading on September 23, and earlier in the day reached a peak gain of about 13%. The company announced a technological breakthrough in quantum computing and a new partnership with AI chipmaker Nvidia.

IonQ announced that it has demonstrated the industry’s first end-to-end real-time quantum error decoder. “Quantum error correction is critical to building practical, error-resilient quantum computers because physical qubits are inherently sensitive to environmental noise,” the company said.

The new technology allows a standard central processing unit (CPU) to detect, correct, and decode errors in a quantum computer as they occur, while continuously running in the background, CNBC explained. A successful test could eliminate one of the industry’s major pain points: previous systems were easily overloaded when correcting errors, leading to delays, the network added.

“The successful verification of real-time decoding on hundreds of logical qubits and over a million logical operations is an important milestone. Moreover, the fact that our decoder runs on a single CPU paves the way for practical, commercial fault-tolerant quantum computing,” said Nicolas Delfoss, head of quantum research at IonQ, as quoted in the company’s press release.

On Wednesday, IonQ also announced that it will install its Superion 256 quantum computer at the Nvidia Center for Accelerated Quantum Research in Boston, where the system will be directly connected to the AI chip manufacturer’s infrastructure.

"We view this as the beginning of an exciting era of hybrid quantum-classical computing," said Niccolò de Masi, chairman of the board of directors and CEO of IonQ, as quoted by the company.

Businesses will be able to use the system for research in financial modeling and portfolio optimization, as well as for chemical calculations in drug development. IonQ's partners include pharmaceutical companies such as AstraZeneca, according to CNBC.

IonQ shares are currently trading at about 5% below their early 2026 levels. However, most analysts tracking the stock recommend buying it: the stock has 12 “Buy” ratings versus three “Hold” ratings, according to MarketWatch. There are no sell recommendations. The average price target of $69.25 implies a rise of nearly 70% from the closing price on September 22.

This article was AI-translated and verified by a human editor